Brind.

EXEL announced that its drug candidate, zanzalintinib, inhibits MET activity and also shows activity against MER.

3 reports, 2 independent Updated Jul 1
Gone quiet
Reports
3
Developments
2
Repetition
33%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

EXEL announced that its drug candidate, zanzalintinib, inhibits MET activity and also shows activity against MER.

Who's involved

What this event is mainly about
EXELMetMer

How it developed

Newest first. Tap a step to see who reported it.
  1. FDA reviews application for zanzalintinib combination therapy.1 source
  2. zanzalintinib shown to inhibit MET and MER activities.1 source

Keep exploring

The entities involved

  • EXEL

    Czech company

    Nothing else this week.

  • Met

    river in Komi, Russia, tributary of Lepyu, upper tributary of Sysola

    Nothing else this week.

  • Mer

    Norwegian operator of charging stations

    Nothing else this week.

Coverage

Newest first; wire copies grouped
  • yahoo.com
  • ZacksWill Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth? Exelixis (EXEL) is developing zanzalintinib — a next-generation oral investigational tyrosine kinase inhibitor (TKI) — which inhib
  • Unknown outlet